CRISPR Therapeutics provided updates on its in vivo cardiovascular disease programs, including new Phase 1 clinical data for CTX310, targeting ANGPTL3. The additional data continued to demonstrate dose-dependent reductions in triglycerides (TG) of up to 82% and low-density lipoprotein (LDL) of up to 86%. The therapy maintained a well-tolerated safety profile, reinforcing the potential of its lipid nanoparticle (LNP) delivery platform.
The company anticipates presenting complete Phase 1 data for CTX310 at a medical meeting in the second half of 2025. This continued positive data for CTX310 is a crucial validation of CRISPR Therapeutics' in vivo gene editing capabilities for prevalent severe monogenic and common diseases. The program is advancing with its dose-finding study.
However, CRISPR Therapeutics also announced a revised timeline for CTX320, its program targeting the LPA gene. A data update for CTX320 is now expected in the first half of 2026, a delay from the previously anticipated second quarter of 2025. This adjustment reflects a strategic decision to incorporate emerging insights from the evolving Lp(a) treatment landscape. Additionally, the preclinical in vivo cardiovascular program CTX340 is advancing toward IND/CTA filings for refractory hypertension.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.